Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature

Summary

This trial will study the effectiveness of ACT001 in adult patients whose Glioblastoma have recurred with a STAT3-high signature after standard-of-care treatment with at least radiation therapy.

Timeline

Start

2025-03-22

Primary completion

2026-05

Completion

2026-05

Outcome

Outcome not reported

Stopped (Business): “Study team is finding new fundings for the study”

Drugs

Indications